World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
43725
World Ranking
11989
National Ranking
484

Overview

Kerry J. Savage is affiliated with the University of British Columbia in Canada. Their research primarily focuses on medicine, with a significant concentration in pathology and forensic medicine, oncology, genetics, pulmonary and respiratory medicine, and immunology.

The scientist's main areas of study encompass lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, CAR-T cell therapy, viral-associated cancers and disorders, lung cancer treatments and mutations, CNS lymphoma diagnosis and treatment, and cancer immunotherapy and biomarkers.

Frequent co-authors collaborating with Kerry J. Savage include Laurie H. Sehn, David W. Scott, Diego Villa, Graham W. Slack, and Alina S. Gerrie.

Publication venues commonly featuring their work are Blood, Clinical Lymphoma Myeloma & Leukemia, Hematological Oncology, Journal of Clinical Oncology, and Blood Advances.

Recent notable papers include:

  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma, 2022, New England Journal of Medicine
  • The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma, 2021, Annals of Oncology
  • Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma, 2020, Journal of Clinical Oncology
  • Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies, 2021, Clinical Cancer Research
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial, 2021, The Lancet Haematology

Best Publications

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

    Laurie H. Sehn;Brian Berry;Mukesh Chhanabhai;Catherine Fitzgerald

  • ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project

    Kerry J. Savage;Nancy Lee Harris;Julie Marie Vose;Fred Ullrich

  • Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

    Nathalie A. Johnson;Graham W. Slack;Kerry J. Savage;Joseph M. Connors

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

    Kerry J. Savage;Nathalie A. Johnson;Susana Ben-Neriah;Joseph M. Connors

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

    Nathalie A. Johnson;Kerry J. Savage;Olga Ludkovski;Susana Ben-Neriah

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

    Christian Steidl;Sohrab P. Shah;Bruce W. Woolcock;Lixin Rui

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

    Owen A. O'Connor;Steven Horwitz;Tamás Masszi;Achiel Van Hoof

  • Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

    K. J. Savage;M. Chhanabhai;R. D. Gascoyne;J. M. Connors

  • Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

    Dennis D. Weisenburger;Kerry J. Savage;Nancy Lee Harris;Randy D. Gascoyne

  • Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies

    David W. Scott;Anja Mottok;Daisuke Ennishi;George W. Wright

Frequent Co-Authors

Joseph M. Connors
Joseph M. Connors University of British Columbia
Randy D. Gascoyne
Randy D. Gascoyne BC Cancer Agency
Christian Steidl
Christian Steidl University of British Columbia
David Scott
David Scott Ascension Health
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Ryan D. Morin
Ryan D. Morin Simon Fraser University
Marco A. Marra
Marco A. Marra University of British Columbia
Sohrab P. Shah
Sohrab P. Shah Memorial Sloan Kettering Cancer Center
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways and online degrees can open many options for those interested in medicine or healthcare careers. For working nurses aiming to advance quickly, pursuing easy dnp programs can provide a flexible route to leadership roles without stepping away from clinical duties.

Entry-level professionals looking to join the field rapidly may benefit from fast track medical lpn programs. These courses allow students to gain practical nursing skills swiftly and efficiently, making them ideal for those eager to start working.

Specializing further is also possible—mental health is a growing focus, and enrolling in online msn pmhnp programs lets qualified nurses become psychiatric mental health nurse practitioners in a flexible online format.

For those interested in the administrative side of healthcare, a bachelors in health administration can lead to management roles in hospitals, clinics, and other organizations—often at a lower cost through online study.

Best Scientists Citing Kerry J. Savage

Trending Scientists